Supplemental Table 1 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Ashwin Gollerkeri
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
106Publications signalées
4877Citations signalées
0Affiliations récentes
Les domaines associés
Colorectal Cancer Treatments and StudiesCancer-related Molecular PathwaysLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysCancer Treatment and Pharmacology
Les publications récentes
Supplemental Figure 6 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Figure 1 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Table 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Figure 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Table 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Figure 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Table 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Figure 7 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Figure 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Table 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
Supplemental Figure 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Yogesh K. Chutake, Michele Mayo, Nancy Dumont, Jessica Filiatrault et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.